articleNew England Journal of MedicineJan 26, 2022BRONZE OA

Homologous and Heterologous Covid-19 Booster Vaccinations

University of Maryland, Baltimore · Baylor College of Medicine · +19 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

Background

Although the three vaccines against coronavirus disease 2019 (Covid-19) that have received emergency use authorization in the United States are highly effective, breakthrough infections are occurring. Data are needed on the serial use of homologous boosters (same as the primary vaccine) and heterologous boosters (different from the primary vaccine) in fully vaccinated recipients.

Methods

virus particles, or BNT162b2 (Pfizer-BioNTech) at a dose of 30 μg. The primary end points were safety, reactogenicity, and humoral immunogenicity on trial days 15 and 29.

No related works found for this paper.

Funding